Healthcare provider profile · identity verified

Cherry Lin, MD

Internal Medicine · PLEASANTON, CA · NPI 1104904283

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	391	139
Levothyroxine Sodium	Levothyroxine Sodium	317	100
Hydrochlorothiazide	Hydrochlorothiazide	281	104
Lisinopril	Lisinopril	265	94
Amlodipine Besylate	Amlodipine Besylate	250	97
Losartan Potassium	Losartan Potassium	226	72
Simvastatin	Simvastatin	213	75
Atenolol	Atenolol	162	58
Alendronate Sodium	Alendronate Sodium	148	54
Fluticasone Propionate	Fluticasone Propionate	125	51
Albuterol Sulfate Hfa	Albuterol Sulfate	105	59
Metoprolol Tartrate	Metoprolol Tartrate	104	41
Alvesco	Ciclesonide	101	44
Metformin Hcl Er	Metformin Hcl	91	33
Trazodone Hcl	Trazodone Hcl	87	28
Furosemide	Furosemide	83	31
Omeprazole	Omeprazole	83	22
Famotidine	Famotidine	80	31
Ibuprofen	Ibuprofen	80	45
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	78	26
Lovastatin	Lovastatin	76	23
Potassium Chloride	Potassium Chloride	75	23
Metformin Hcl	Metformin Hcl	67	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	66	20
Sertraline Hcl	Sertraline Hcl	62	19
Glipizide	Glipizide	58	19
Tamsulosin Hcl	Tamsulosin Hcl	55	16
Gabapentin	Gabapentin	54	29
Metoprolol Succinate	Metoprolol Succinate	54	18
Terazosin Hcl	Terazosin Hcl	54	17
Triamcinolone Acetonide	Triamcinolone Acetonide	52	33
Fluoxetine Hcl	Fluoxetine Hcl	50	19
Pantoprazole Sodium	Pantoprazole Sodium	50	16
Spironolactone	Spironolactone	49	15
Allopurinol	Allopurinol	37	14
Wixela Inhub	Fluticasone Propion/Salmeterol	36	13
Carvedilol	Carvedilol	35	11
Pravastatin Sodium	Pravastatin Sodium	32	suppressed
Acyclovir	Acyclovir	31	17
Rosuvastatin Calcium	Rosuvastatin Calcium	28	13
Warfarin Sodium	Warfarin Sodium	28	suppressed
Clonazepam	Clonazepam	27	suppressed
Spiriva Respimat	Tiotropium Bromide	27	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	16
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	26	26
Nortriptyline Hcl	Nortriptyline Hcl	26	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	25	suppressed
Prednisone	Prednisone	25	11
Xarelto	Rivaroxaban	25	suppressed
Amoxicillin	Amoxicillin	24	15
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	23	suppressed
Glipizide Er	Glipizide	23	suppressed
Lorazepam	Lorazepam	23	15
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Jardiance	Empagliflozin	20	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	20	suppressed
Verapamil Er	Verapamil Hcl	20	suppressed
Baclofen	Baclofen	19	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	19	suppressed
Meloxicam	Meloxicam	18	12
Ozempic	Semaglutide	18	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	17	15
Eliquis	Apixaban	17	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Tramadol Hcl	Tramadol Hcl	15	suppressed
Colchicine	Colchicine	14	suppressed
Hydrocortisone	Hydrocortisone	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	12
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Finasteride	Finasteride	13	suppressed
Fluocinonide	Fluocinonide	13	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Donepezil Hcl	Donepezil Hcl	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Nabumetone	Nabumetone	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Rizatriptan	Rizatriptan Benzoate	12	suppressed
Abiraterone Acetate	Abiraterone Acetate	11	suppressed
Aripiprazole	Aripiprazole	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error